Solasia, Ziopharm Oncology deal

Ziopharm granted Solasia exclusive rights to develop and commercialize IV and oral darinaparsin in 13 Asia-Pacific territories. The IV organic arsenic compound is in Phase II testing for peripheral T cell lymphoma (PTCL), while the oral formulation is in Phase I testing for solid tumors. ...